Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Microbiology

• Publication date

  2006-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JCM.01551-06PMID 17079501PMCID PMC1828974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard

  2008cited by this paper
• Clinical Significance of Azole Antifungal Drug Cross-Resistance in Candida glabrata

  2006cited by this paper
• Performance standards for antimicrobial disk susceptibility tests : approved standard

  2006cited by this paper
• Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

  2006influential reference
• Candida, Cryptococcus, and other yeasts of medical importance.

  2006cited by this paper
• Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy

  2006influential reference
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

  2006cited by this paper
• Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing

  2006cited by this paper
• Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.

  2005influential reference
• Voriconazole for candidosis: an important addition?

  2005cited by this paper
• Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

  2005influential reference
• Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

  2004cited by this paper
• Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida spp

  2004cited by this paper
• Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

  2004influential reference
• Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei

  2003cited by this paper
• Voriconazole treatment for less-common, emerging, or refractory fungal infections.

  2003influential reference
• Evaluation of the Etest and Disk Diffusion Methods for Determining Susceptibilities of 235 Bloodstream Isolates of Candida glabrata to Fluconazole and Voriconazole

  2003cited by this paper
• Voriconazole Salvage Treatment of Invasive Candidiasis

  2003influential reference
• In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis

  2003cited by this paper
• Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001

  2003cited by this paper
• Voriconazole: A New Triazole Antifungal Agent

  2003cited by this paper
• Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole

  2002cited by this paper
• Has antifungal susceptibility testing come of age?

  2002cited by this paper
• Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility

  2002cited by this paper
• In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp

  2002cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).

  2001cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Development and Characterization of Complex DNA Fingerprinting Probes for the Infectious Yeast Candida dubliniensis

  1999cited by this paper
• Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A Reference Method for Testing Clinical Isolates of Common and Emerging Candidaspp., Cryptococcus spp., and Other Yeasts and Yeast-Like Organisms

  1999cited by this paper
• Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora

  1997cited by this paper
• Development of in vitro susceptibility testing criteria and quality control parameters

  1989cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Manual of clinical microbiology

  1975cited by this paper

• ANTIFUNGAL SUSCEPTIBILITY AND BIOFILM PRODUCTION OF CANDIDA SPP. ISOLATED FROM THE ORAL MUCOSA OF DENTURE PATIENTS AND ORTHODONTIC PATIENTS COMPARED TO HEALTHY CONTROLS

  2024cites this paper
• In vitro sensitivity of Candida albicans isolates to antifungal agents and the effect of biofilms on the drug resistance rate

  2024cites this paper
• Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine

  2023cites this paper
• Antifungal Activity of the Essential Oil of Echinops kebericho Mesfin: An In Vitro Study

  2020cites this paper
• Antifungal Susceptibility of Non-albicans Candida Species in A Tertiary Care Hospital, Bulgaria

  2020cites this paper
• Fluconazole

  2020cites this paper
• Antifungal Susceptibility of Candida albicans Isolates at a Tertiary Care Hospital in Bulgaria

  2019cites this paper
• Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

  2019cites this paper
• FLUCONAZOLE INJECTION, USP(in 0.9% Sodium Chloride)For Intravenous Infusion only

  2019cites this paper
• Resistance rates of non-albicans Candida infections in Taiwan after the revision of 2012 Clinical and Laboratory Standards Institute breakpoints

  2019cites this paper
• Dam characteristics associated with pre-weaning diarrhea in mink (Neovison vison)

  2018cites this paper
• In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.

  2018cites this paper
• Detection of azole resistance and ERG 11 point mutations in Candida albicans isolates from tertiary hospitals in the Philippines Moron LS

  2018cites this paper
• Thiobarbiturates as potential antifungal agents to control human infections caused by Candida and Cryptococcus species

  2018cites this paper
• Candida Urinary Tract Infections; Treatment Protocol

  2017cites this paper
• Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis

  2017cites this paper
• Drug susceptibility of Candida isolated from the surfaces of mobile phones and hands

  2017cites this paper
• Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients

  2017cites this paper
• Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

  2016cites this paper
• Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H+ Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2

  2016cites this paper
• Tratamiento de las infecciones fungicas en pacientes con neoplasias hematologicas Treatment of fungal infections in patients with hematologic neoplasia

  2016cites this paper
• Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• Membrane Proteome-Wide Response to the Antifungal Drug Clotrimazole in Candida glabrata: Role of the Transcription Factor CgPdr1 and the Drug:H+ Antiporters CgTpo1_1 and CgTpo1_2*

  2015cites this paper
• Molecular identification and in-vitro antifungal susceptibility testing of Candida species isolated from patients with onychomycosis

  2015cites this paper
• DEPARTMENT OF HEALTH & HUMAN SERVICES

  2015cites this paper
• A n t i f u n g a l A g e n t s Spectrum of Activity, Pharmacology, and Clinical Indications

  2015cites this paper
• In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey

  2015cites this paper
• Mechanisms of Resistance to Antifungal Agents

  2015cites this paper
• Invasive Fungal Infections and Approaches to Their Diagnosis

  2015cites this paper
• Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases

  2015cites this paper
• Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria

  2014cites this paper
• SPECIES DISTRIBUTION AND ANTIFUNGAL SUSCEPTIBILITY OF YEASTS ISOLATED FROM VAGINAL MUCOSA

  2014cites this paper
• Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species

  2014cites this paper
• and Interpretive Criteria of Candida by Using CLSI Methods and Caspofungin among 4 , 290 Clinical Isolates To Predict Susceptibility and Resistance to Use of Anidulafungin as a Surrogate Marker

  2014cites this paper
• SUSCEPTIBILITY OF Candida spp. ISOLATED FROM BLOOD CULTURES AS EVALUATED USING THE M27-A3 AND NEW M27-S4 APPROVED BREAKPOINTS

  2014cites this paper
• Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran.

  2014cites this paper
• Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values

  2014cites this paper
• Antifungal susceptibility patterns of germ tube positive versus germ

  2013cites this paper
• Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria

  2013cites this paper
• Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species

  2013influential citation
• P1507440 Fluconazole Tablets USP (INSERT) $.FH8

  2013cites this paper
• Antifungal Activities of Diphenyl Diselenide alone and in Combination with Fluconazole or Amphotericin B against Candidaglabrata

  2013cites this paper
• Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents

  2013cites this paper
• Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies

  2012cites this paper
• Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross‐resistance to triazole antifungal agents

  2012cites this paper
• The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.

  2012cites this paper
• Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi‐centre study

  2012cites this paper
• Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.

  2012cites this paper
• Biographical Feature: Michael A. Pfaller, M.D

  2012cites this paper
• Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use

  2012cites this paper
• Azole‐resistant Candida spp. – emerging pathogens?

  2012cites this paper
• In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis

  2011cites this paper
• Evaluation of Antifungal Susceptibility Testing with Microdilution and Etest Methods of Candida Blood Isolates

  2011cites this paper
• Antifungal Susceptibility of Bloodstream Candida Isolates in Sfax Hospital: Tunisia

  2011cites this paper
• Эмпирическая терапия инвазивного кандидоза в отделениях реанимации и интенсивной терапии: современное состояние проблемы

  2011cites this paper
• Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

  2011cites this paper
• New antifungal agents for the treatment of candidaemia.

  2010cites this paper
• Epidemiology of Invasive Mycoses in North America

  2010influential citation
• Canadian clinical practice guidelines for invasive candidiasis in adults.

  2010cites this paper
• [Anidulafungin: a new therapeutic option in systemic candidiasis].

  2010cites this paper
• Epidemiology of nosocomial candidaemia in a university hospital: a 12-year study

  2010cites this paper
• Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

  2010cites this paper
• Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

  2010cites this paper
• Fixed-Ratio Combination Testing of an Echinocandin, Anidulafungin, and an Azole, Voriconazole, against 1,467 Candida Species Isolates

  2010cites this paper
• In vitro activity of voriconazole against Mexican oral yeast isolates

  2010cites this paper
• A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

  2009influential citation
• Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007

  2009cites this paper
• Trends in antifungal susceptibility testing using CLSI reference and commercial methods

  2009cites this paper
• Antifungal activity of the benzo[c]phenanthridine alkaloids from Chelidonium majus Linn against resistant clinical yeast isolates.

  2009cites this paper
• Issues in Anti-infective Management

  2009cites this paper
• Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of Candida spp. and Other Yeasts

  2009influential citation
• [Treatment of fungal infections in patients with hematologic neoplasia].

  2009cites this paper
• Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

  2009cites this paper
• Intra-abdominal sepsis: newer interventional and antimicrobial therapies.

  2009cites this paper
• New developments in the antifungal susceptibility testing of Candida

  2008cites this paper
• Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.

  2008cites this paper
• Susceptibility to Voriconazole, Fluconazole, and Ketoconazole of Yeast Isolated from Patients with Hematological Malignancies

  2008cites this paper
• L'albumine endogène : un pouvoir anti-oxydant majeur

  2008cites this paper
• Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

  2008influential citation
• Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.

  2008cites this paper
• Resistance to Antifungal Agents: Mechanisms and Clinical Impact

  2008cites this paper
• Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints

  2008cites this paper
• Prostatic Abscess With Candida glabrata Treated With Micafungin

  2008cites this paper
• Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.

  2007cites this paper
• Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp

  2007cites this paper
• Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing

  2007cites this paper
• Actividad antifúngica in vitro de voriconazol: Nuevos datos después de los primeros años de experiencia clínica

  2007cites this paper
• [In vitro antifungal activity of voriconazole: New data after the first years of clinical experience].

  2007cites this paper
• Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance.

  2007cites this paper
• Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing

  2007cites this paper
• Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance.

  2007cites this paper
• Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program

  2007influential citation
• DIFLUCAN ® ( Fluconazole Tablets ) ( Fluconazole Injection-for intravenous infusion only ) ( Fluconazole for Oral Suspension )

  year unknowncites this paper
• AF 35383 Format 131401 # 016 D Flat : 20 . 0 ” x 13 . 75 ” Folded : 6 . 0 ” x 1 . 375 ” PMS Black 12 / 13 / 13 Head to Head

  year unknowncites this paper